This trend was first noted in profiling of human ovarian cancer cell lines, which found that high GBP1 expression strongly correlated with paclitaxel resistance and that its knock-out restored treatment sensitivity (60, 61). The gene discussed is GBP1; the disease is ovarian cancer.